DrugPatentWatch Database Preview
Lubiprostone - Generic Drug Details
What are the generic drug sources for lubiprostone and what is the scope of lubiprostone patent protection?
Lubiprostone has two hundred and nine patent family members in twenty-eight countries.
There are nine drug master file entries for lubiprostone. Six suppliers are listed for this compound.
Summary for lubiprostone
International Patents: | 209 |
US Patents: | 16 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 9 |
Suppliers / Packagers: | 6 |
Bulk Api Vendors: | 66 |
Clinical Trials: | 43 |
Patent Applications: | 770 |
Drug Prices: | see low prices |
DailyMed Link: | lubiprostone at DailyMed |
Pharmacology for lubiprostone
Drug Class | Chloride Channel Activator |
Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for lubiprostone
Synonyms for lubiprostone
(-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid |
(-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid |
(2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-heptanoic acid |
1263283-38-0 |
136790-76-6 |
333963-40-9 |
7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid |
7-((2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl)heptanoic acid |
7-((2R,4aR,5S,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl)heptanoic acid |
7-[(1R,4R,6R,9R)-4-(1,1-Difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo[4.3.0]non-9-yl]heptanoic acid |
7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid |
7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[e]pyran-5-yl]heptanoic acid |
7-[(2R,4aR,5S,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid |
7-[(2R,4aR,5S,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-octahydrocyclopenta[b]pyran-5-yl]heptanoic acid |
7-[2-(1,1-DIFLUOROPENTYL)-2-HYDROXY-6-OXO-HEXAHYDROCYCLOPENTA[B]PYRAN-5-YL]HEPTANOIC ACID |
89248-EP2275419A2 |
89248-EP2305652A2 |
963L409 |
AC-1863 |
AC1L4IXH |
AC1LCVGZ |
AK341743 |
AKOS015896617 |
AKOS015896639 |
AKOS030241065 |
Amitiza |
Amitiza (TN) |
Amitiza, RU-0211, SPI-0211, Lubiprostone |
AN-6562 |
API0003227 |
BC677681 |
Bicyclic lubiprostone |
C13707 |
C20H32F2O5 |
C28H28F2O5 |
CAS-136790-76-6 |
CHEBI:34945 |
CHEMBL1201134 |
CHEMBL3348939 |
CTK8E7624 |
D00CTS |
D04790 |
DB01046 |
DSSTox_CID_28565 |
DSSTox_GSID_48639 |
DSSTox_RID_82837 |
DTXSID5048639 |
FT-0670870 |
FT-0697010 |
GTPL4242 |
HE335962 |
I06-2314 |
I06-2319 |
J-006909 |
J-521658 |
KS-00000XLM |
LP012735 |
LP012736 |
LS-186535 |
LS-187360 |
Lubiprostone (JAN/USAN/INN) |
Lubiprostone [USAN] |
Lubiprostone hemiketal |
Lubiprostone related compound 3 |
MFCD08444045 |
MolPort-006-666-405 |
N917 |
NCGC00183105-01 |
Prostan-1-oic acid, 11,15-epoxy-16,16-difluoro-15-hydroxy-9-oxo-, (11alpha,15R)- |
RL03218 |
RP17713 |
RT-013602 |
RU-0211 |
RU0211 |
SC-20086 |
SC-99699 |
SCHEMBL12173275 |
SCHEMBL217184 |
SCHEMBL454016 |
SPI 0211 |
SPI-0211 |
SPI0211 |
Tox21_112986 |
WGFOBBZOWHGYQH-MXHNKVEKSA-N |
X6870 |
YF10093 |
Z6115 |
ZINC4217732 |
US Patents and Regulatory Information for lubiprostone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for lubiprostone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for lubiprostone
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
7,253,295 | Chloride channel opener | ➤ Try a Free Trial |
6,610,732 | Anti-constipation composition | ➤ Try a Free Trial |
8,748,454 | Anti-constipation composition | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents for lubiprostone
Country | Document Number | Estimated Expiration |
---|---|---|
Austria | 522218 | ➤ Try a Free Trial |
Japan | 2011201905 | ➤ Try a Free Trial |
Canada | 2419741 | ➤ Try a Free Trial |
Netherlands | 300757 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for lubiprostone
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
1315485/01 | Switzerland | ➤ Try a Free Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
0757 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: LUBIPROSTON; NATIONAL REGISTRATION NO/DATE: RVG 115891; FIRST REGISTRATION NO/DATE: PL21341/0003 20120910 |
2015000080 | Germany | ➤ Try a Free Trial | PRODUCT NAME: LUBIPROSTON, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 92699.00.00 20150519; FIRST REGISTRATION: VEREINIGTES KOENIGREICH PL 21341/0003 20120910 |
00757 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: LUBIPROSTON; NAT. REGISTRATION NO/DATE: RVG 115891 20150317; FIRST REGISTRATION: |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:









Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.